Certain beaten-up ASX shares could be appealing after dropping noticeably in the last several months, which could have opened up a buying opportunity for brave investors.
Just because a business has fallen doesn't automatically mean it's going to rebound. However, I think the two businesses I'll discuss have been oversold and could be good buys.
In a falling interest rate environment, I think investors could do well with the following ASX shares.
Australian Clinical Labs Ltd (ASX: ACL)
This ASX share is one of Australia's largest private providers of pathology services. It provides pathology services for a range of clients, including doctors, specialists, patients, hospitals, and corporate clients. It's also one of the largest private hospital pathology businesses in Australia.
As the chart below shows, the Australian Clinical Labs share price has declined by approximately a quarter of its value since 25 February 2025.
In the company's FY25 half-year results, it reported total revenue growth of $31.9 million to $369.2 million. Statutory operating profit (EBIT) rose $11 million to $26.9 million, and statutory net profit increased $6.8 million to $11.8 million.
I think this could be a compelling option for investors looking for a relatively defensive business that can deliver growth.
The beaten-up ASX share is looking to drive top-line growth through sustainable and profitable collection centre network expansion and hospital services growth at "margin accretive rates". The company is trading at 13x FY26's estimated earnings according to Commsec, with a potential grossed-up dividend yield of 6.8% including franking credits.
Siteminder Ltd (ASX: SDR)
Siteminder is another ASX share that is now trading at a much cheaper price. It's down approximately 30% from its February 2025 high, as the chart below shows.
This company provides the Siteminder software, which is a hotel distribution and revenue platform. It also offers Little Hotelier, an all-in-one hotel management software that aims to provide pleasing usability and efficiencies for smaller hotels.
The company is growing revenue at a strong rate, so I believe Siteminder's share price decline is only temporary and is likely to recover in the medium term. In the FY25 half-year result, the business reported its annualised recurring revenue increased 18.4% to $216.2 million.
Its increasing scale is helping the company's profit margins increase. In the HY25 result, its underlying gross profit improved by 118 basis points (1.18%) to 66.9% thanks to its operating leverage. This helped the company achieve positive underlying earnings before interest, taxes, depreciation, and amortisation (EBITDA) of $5.3 million, an improvement from the $1.2 million loss in the FY24 first half.
I'm expecting the company to be much more profitable in the next few years and continue winning more hotel customers, with a particular focus on larger ones.
